Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Abstract COVID-19-associated coagulopathy (CAC) is a life-threatening complication of
SARS-CoV-2 infection. However, the underlying cellular and molecular mechanisms driving …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and
uncontrolled inflammation and thrombosis, both of which are responsible for organ damage …

В конце 2019 г. в Китайской Народной Республике (КНР) произошла вспышка новой
коронавирусной инфекции с эпицентром в городе Ухань (провинция Хубэй). Всемирная …

Ischaemia–reperfusion (I–R) injury, initiated via bursts of reactive oxygen species produced
during the reoxygenation phase following hypoxia, is well known in a variety of acute …

Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …

Tissue microcirculation is essential for the maintenance of organ homeostasis. Following
acute infections, activation of coagulation and inflammation, which are critical …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …